All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F18%3A00069329" target="_blank" >RIV/00159816:_____/18:00069329 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.4244/EIJ-D-18-00762" target="_blank" >http://dx.doi.org/10.4244/EIJ-D-18-00762</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4244/EIJ-D-18-00762" target="_blank" >10.4244/EIJ-D-18-00762</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial

  • Original language description

    Aims: The aim of this study was to evaluate the safety and efficacy of the BioMime sirolimus-eluting coronary stem (SES) compared to the XIENCE family of everolimus-eluting coronary stents (EES) in the treatment of patients with de novo native coronary artery lesions. Methods and results: The meriT-V is a prospective, multicentre, randomised, open-label, active-controlled, non-inferiority trial. A total of 256 patients with up to two de novo native coronary artery lesions were enrolled and randomly assigned (2:1) to BioMime SES or XIENCE EES. BioMime SES was non-inferior to XIENCE EES for the primary endpoint of in-stent late lumen loss (0.15 +/- 0.27 mm vs. 0.15 +/- 0.29 mm; difference: -0.006 mm; 95% confidence interval: -0.085 to 0.072; p=0.87; p for non-inferiority &lt;0.0001) at nine-month follow-up. The major adverse cardiac events rate was numerically lower in the BioMime SES group (2.98% vs. 7.14%; p=0.13), driven by a statistically significant lower risk of any myocardial infarction (0.60% vs. 4.76%; p=0.03), when compared with the XIENCE EES group. There was no difference in target vessel myocardial infarction (p=0.62) between the groups. There was no definite or probable stent thrombosis in either group. Conclusions: In the treatment of de novo native coronary artery lesions, the biodegradable polymer ultrathin SES (BioMime) was non-inferior to a durable polymer EES (XIENCE) at nine-month follow-up. Further studies powered for clinical endpoints are needed.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Eurointervention

  • ISSN

    1774-024X

  • e-ISSN

  • Volume of the periodical

    14

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    FR - FRANCE

  • Number of pages

    8

  • Pages from-to

    1207-1214

  • UT code for WoS article

    000452498600012

  • EID of the result in the Scopus database

    2-s2.0-85058636243